Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation

International Journal of Hematology

Volumn 97, Issue 4, 2013, Pages 511-519

  Chinen, Yoshiaki ^a   Kuroda, Junya ^a   Ohshiro, Muneo ^a,b   Shimura, Yuji ^a   Mizutani, Shinsuke ^a   Nagoshi, Hisao ^a   Sasaki, Nana ^a   Nakayama, Ryuko ^a   Kiyota, Miki ^a   Yamamoto Sugitani, Mio ^a   Kobayashi, Tsutomu ^a   Matsumoto, Yosuke ^a   Horiike, Shigeo ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

Adamts 13; Disseminated intravascular coagulation; Hematologic disorders; Hemorrhagic events

Indexed keywords

BIOLOGICAL MARKER; FRESH FROZEN PLASMA; RECOMBINANT THROMBOMODULIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; RECOMBINANT PROTEIN; THROMBOMODULIN;

ABDOMINAL BLEEDING; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DUODENUM BLEEDING; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MUSCLE BLEEDING; PLEURA DISEASE; PREDICTIVE VALUE; REMISSION; RETROPERITONEAL HEMATOMA; RISK ASSESSMENT; URINARY TRACT HEMORRHAGE; VERY ELDERLY; BLOOD; CASE REPORT; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; ENZYME ACTIVATION; FATALITY; HEMORRHAGE; MIDDLE AGED; TREATMENT OUTCOME;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; ENZYME ACTIVATION; FATAL OUTCOME; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84891681917     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1308-x     Document Type: Article

References (43)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586-92.
2. Toh CH, Dennis M. Disseminated intravascular coagulation: old disease, new hope. BMJ. 2003;327:974-7.
3. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis(ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-30.
4. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-30.
5. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost. 2001;27:593-604.
6. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35:2191-5.
7. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24-33.
8. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, OPTIMIST Trial Study Group, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47.
9. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, KyberSept Trial Study Group, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.
10. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176:483-90.
11. Jaimes F, De-La-Rosa G, Morales C, Fortich F, Arango C, Aguirre D, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37:1185-96.
12. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864-75.
13. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000;28: 31-3.
14. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91: 2850-60.
15. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
16. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332-41.
17. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882-8.
18. Aikawa N, Shimazaki S, Yamamoto Y, Saito H, Maruyama I, Ohno R, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock. 2011;35:349-54.
19. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002;196:561-4.
20. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267-74.
21. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 2008;112:3661-70.
22. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41.
23. Ohshiro M, Kuroda J, Kobayashi Y, Akaogi T, Kawata E, Uoshima N, et al. ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin. Am J Hematol. 2012;87:116-9.
24. Brunning RD, Matutes E, Harris NL, Flandrin G, Vardiman J, Bennett J, et al. Acute myeloid leukaemia not otherwise categorised. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid Tissues. Lyon: IARC Press; 2001. p. 91-105.
25. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care. 2011;15:R123.
26. Tsubokura M, Yamashita T, Inagaki L, Kobayashi T, Kakihana K, Wakabayashi S, et al. Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation. Bone Marrow Transplant. 2011;46: 1030-1.
27. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922-4.
28. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-6.
29. Gerritsen HE, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98:1654-61.
30. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100: 4033-9.
31. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-94.
32. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-94.
33. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589-600.
34. Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol. 2010;91:36-45.
35. Tonooka K, Ito H, Shibata T, Ozaki S. Recombinant human soluble thrombomodulin for treatment of thrombotic microangiopathy associated with lupus nephritis. J Rheumatol. 2012;39: 1766-7.
36. Moore JC, Hayward CP, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001;98:1842-6.
37. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710-3.
38. Hyun J, Kim HK, Kim JE, Lim MG, Jung JS, Park S, et al. Correlation between plasma activity of ADAMTS-13 andcoagulopathy, and prognosis in disseminated intravascular coagulation. Thromb Res. 2009;124:75-9.
39. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105:1085-93.
40. Hiura H, Matsui T, Matsumoto M, Hori Y, Isonishi A, Kato S, et al. Proteolytic fragmentation and sugar chains of plasma ADAMTS13 purified by a conformation-dependent monoclonal antibody. J Biochem. 2010;148:403-11.
41. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med. 2008;205:2065-74.
42. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005;115:1267-74.
43. Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A, et al. Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13- mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant. 2007;40:251-9.